Summary
73 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 12 USD is left as net profit.
- Revenue grew by 17% a year over the last 3 years.
- It holds more cash than debt: $12.9M against $6.39M.
- It earns 10.0 USD a year on every 100 USD of invested capital.
What to watch
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 15.5 USD for 1 USD of yearly profit. Over the last five years it was 9.1 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 18% a year over 5 years. Over the last 3 years it grew by 17% a year. Earnings per share grew by 0.8% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 73 USD
- Sales and administration 9.8 USD
- Taxes and other 4.3 USD
- Net profit 13 USD
Net profit, industry median (Chemicals - Specialty) 5.9 USD
Out of every 100 USD of revenue, 13 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.